Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus.
暂无分享,去创建一个
J A Madrigal | C Baboonian | J. Madrigal | J. Goldman | C. Baboonian | C. L. Morgan | J Goldman | C. Morte | C L Morgan | C Morte | A Solache | A I Dodi | I Scott | B Zal | J E Grundy | B. Zal | I. Scott | J. Grundy | A. Solache | A. Dodi | Jane E. Grundy | Alejandra Solache | Claire L. Morgan | Carles Morte | Iain Scott | Christina Baboonian | John Goldman | Jane E. Grundy | J. E. Grundy
[1] M. Weekes,et al. The Memory Cytotoxic T-Lymphocyte (CTL) Response to Human Cytomegalovirus Infection Contains Individual Peptide-Specific CTL Clones That Have Undergone Extensive Expansion In Vivo , 1999, Journal of Virology.
[2] P. Parham,et al. The influence of exogenous peptide on β2–microglobulin exchange in the HLA complex: analysis in real-time , 1998, Immunogenetics.
[3] L. Hsiao,et al. A sensitive ELISPOT assay to detect low-frequency human T lymphocytes. , 1997, Journal of immunological methods.
[4] J. York,et al. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. , 1997, Blood.
[5] H. Rammensee,et al. Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptide. , 1997, The Journal of general virology.
[6] P. A. Peterson,et al. The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. , 1997, Immunity.
[7] X. Jin,et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL , 1996, Journal of virology.
[8] J. Grundy,et al. Cytomegalovirus induced up-regulation of LFA-3 (CD58) and ICAM-1 (CD54) is a direct viral effect that is not prevented by ganciclovir or foscarnet treatment. , 1996, Transplantation.
[9] U. Koszinowski,et al. Human cytomegalovirus inhibits peptide translocation into the endoplasmic reticulum for MHC class I assembly. , 1996, The Journal of general virology.
[10] S. H. van der Burg,et al. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. , 1996, Journal of immunology.
[11] S. H. van der Burg,et al. An HLA class I peptide-binding assay based on competition for binding to class I molecules on intact human B cells. Identification of conserved HIV-1 polymerase peptides binding to HLA-A*0301. , 1995, Human immunology.
[12] L. Sun,et al. Multiple independent loci within the human cytomegalovirus unique short region down-regulate expression of major histocompatibility complex class I heavy chains , 1995, Journal of virology.
[13] P. Klenerman,et al. The effects of natural altered peptide ligands on the whole blood cytotoxic T lymphocyte response to human immunodeficiency virus , 1995, European journal of immunology.
[14] R. Zinkernagel,et al. Immunobiology of cytotoxic T-cell escape mutants of lymphocytic choriomeningitis virus , 1995, Journal of virology.
[15] D. Speiser,et al. Oligotyping of HLA-A2, -A3, and -B44 subtypes. Detection of subtype incompatibilities between patients and their serologically matched unrelated bone marrow donors. , 1994, Human immunology.
[16] J. Sidney,et al. Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. , 1994, Molecular immunology.
[17] A. Sette,et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells , 1994, Nature.
[18] S. Riddell,et al. Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus‐specific cytotoxic T lymphocytes , 1994, Journal of medical virology.
[19] H. Grey,et al. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[20] K. Parker,et al. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. , 1994, Journal of immunology.
[21] S. Riddell,et al. Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus , 1993, Journal of virology.
[22] M. Masucci,et al. HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11+ population. , 1993, Science.
[23] G. Wilkinson,et al. Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector. , 1992, Nucleic acids research.
[24] M. Bednarek,et al. The minimum peptide epitope from the influenza virus matrix protein. Extra and intracellular loading of HLA-A2. , 1991, Journal of immunology.
[25] B. Walker,et al. An optimal viral peptide recognized by CD8+ T cells binds very tightly to the restricting class I major histocompatibility complex protein on intact cells but not to the purified class I protein. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[26] H. Rammensee,et al. Fine specificity of cytotoxic T lymphocytes primed in vivo either with virus or synthetic lipopeptide vaccine or primed in vitro with peptide , 1991, The Journal of experimental medicine.
[27] S. Riddell,et al. Cytotoxic T cells specific for cytomegalovirus: a potential therapy for immunocompromised patients. , 1991, Reviews of infectious diseases.
[28] Timothy E. Elliott,et al. A quantitative assay of peptide‐dependent class I assembly , 1991, European journal of immunology.
[29] M. Keller,et al. Evidence for idiotypic sharing between conventional and naturally activated B cells , 1991, European journal of immunology.
[30] S. Riddell,et al. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. , 1991, Blood.
[31] H. Rammensee,et al. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules , 1991, Nature.
[32] W. Britt,et al. Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. , 1991, Journal of immunology.
[33] P. Cresswell,et al. Presentation of viral antigen controlled by a gene in the major histocompatibility complex , 1990, Nature.
[34] J. Sissons,et al. Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses , 1988, The Journal of experimental medicine.
[35] T. Leanderson,et al. Clonal Selection in B‐Cell Growth and Differentiation , 1987, Immunological reviews.
[36] N. Shastri,et al. The Choice of T‐Cell Epitopes Utilized on a Protein Antigen Depends on Multiple Factors Distant from, as well as at the Determinant Site , 1987, Immunological Reviews.
[37] K Kumagai,et al. A simple method to eliminate the antigenicity of surface class I MHC molecules from the membrane of viable cells by acid treatment at pH 3. , 1987, Journal of immunological methods.
[38] A. McMichael,et al. Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2 , 1987, Nature.
[39] B. Barrell,et al. Primary structure and transcription of the genes coding for the two virion phosphoproteins pp65 and pp71 of human cytomegalovirus , 1987, Journal of virology.
[40] P. Cresswell,et al. Impaired assembly and transport of HLA‐A and ‐B antigens in a mutant TxB cell hybrid. , 1986, The EMBO journal.
[41] A. McMichael,et al. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides , 1986, Cell.
[42] H. Orr,et al. Mutations that impair a posttranscriptional step in expression of HLA-A and -B antigens. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[43] A. Riggs,et al. Cloning and physical mapping of a gene fragment coding for a 64-kilodalton major late antigen of human cytomegalovirus. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[44] W. Gibson,et al. Selection of particles and proteins for use as human cytomegalovirus subunit vaccines. , 1984, Birth defects original article series.
[45] J. Manischewitz,et al. Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. , 1982, The New England journal of medicine.
[46] C. Barnstable,et al. Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C, antigens. , 1979, Journal of immunology.
[47] C. Barnstable,et al. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis , 1978, Cell.